Skip to main content
OpenTrials
Completed

NCT Number: NCT03723772

A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a Week

This study compares the new long-acting insulin 287 with the marketed insulin glargine for use in type 1 diabetes. The study will test how insulin is taken up in your blood, how long it stays there and how the blood sugar is lowered. The participant will get both of the insulins in a random order. Insulin 287 is a new medicine while insulin glargine is already approved for the treatment of diabetes and can be prescribed by a doctor. The participant will get 8 weekly doses of insulin 287 and 14 daily doses of insulin glargine. There will also be a run-in period of 2 days to 4 weeks with daily doses of insulin glargine before you start the insulin 287 period. All doses will be injected under the skin. The study will last for about 16 to 24 weeks. The participant will have 27 visits with the study doctor.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Mellitus, Type 1 Autoimmune Diseases Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Immune System Diseases Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year–64 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Profil Institut für Stoffwechselforschung GmbH

Neuss, 41460, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female, aged 18-64 years (both inclusive) at the time of signing informed consent
  • Diagnosed with type 1 diabetes mellitus greater than or equal to 1 year prior to the day of screening
  • Current daily basal insulin treatment greater than or equal to 0.2 U/kg/day
  • Body mass index between 18.5 and 29.0 kg/m^2 (both inclusive)
  • HbA1c less than or equal to 9.0%

Exclusion criteria

  • History or presence of any clinically relevant respiratory, metabolic, renal, hepatic, gastrointestinal or endocrinological conditions. Subjects with complications associated to diabetes can be included only if they are judged to be mild by the investigator. Subjects with other comorbidities (e.g. dyslipidaemia, hypertension and hypothyroidism) can be included if they have a stable treatment and are in adequate control according to the judgement of the investigator- Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice)
  • Known or suspected hypersensitivity to trial products or related products

Treatment and study plan

Insulin icodec

Drug

Participants will receive subcutaneous injections of insulin 287 once weekly for 8 weeks

Other names: Insulin 287

IGlar U100

Drug

Participants will receive subcutaneous injections of insulin glargine once weekly for 2 weeks.

Primary outcomes

  1. AUCI287,τ,SS - Area under the serum insulin 287 concentration-time curve during one dosing interval at steady state

    Time frame: From 0 to 168 hours after trial product administration (Day 50)

    Measured in pmol*h/L

Secondary outcomes

  1. AUCGIR,16-52h,SS (for insulin 287) - Area under the glucose infusion rate-time curve at steady state

    Time frame: From 16 to 52 hours after trial product administration (Day 50)

    Measured in mg/kg

  2. AUCGIR,138-168h,SS (for insulin 287) - Area under the glucose infusion rate-time curve at steady state

    Time frame: From 138 to 168 hours after trial product administration (Day 50)

    Measured in mg/kg

  3. GIRmax,16-52h, SS (for insulin 287) - Maximum observed glucose infusion rate at steady state

    Time frame: From 16 to 52 hours after trial product administration (Day 50)

    Measured in mg/(kg*min)

  4. GIRmax,138-168h, SS (for insulin 287) - Maximum observed glucose infusion rate at steady state

    Time frame: From 138 to 168 hours after trial product administration (Day 50)

    Measured in mg/(kg*min)

  5. AUCGIR,0-24h,SS (for insulin glargine) - Area under the glucose infusion rate-time curve at steady state

    Time frame: From 0 to 24 hours after trial product administration (Day 14)

    Measured in mg/kg

  6. GIRmax,0-24h, SS (for insulin glargine) - Maximum observed glucose infusion rate at steady state

    Time frame: From 0 to 24 hours after trial product administration (Day 14)

    Measured in mg/(kg*min)

  7. AUCI287,0-168h,FD (from insulin 287) - Area under the serum insulin 287 concentration-time curve after the first dose

    Time frame: From 0 to 168 hours after trial product administration (Day 1)

    Measured in pmol*h/L

  8. Cmax,I287,FD (for insulin 287) - Maximum observed serum insulin 287 concentration after the first dose

    Time frame: From 0 to 168 hours after trial product administration (Day 1)

    Measured in pmol/L

  9. tmax,I287,FD (for insulin 287) - Time to maximum observed serum insulin 287 concentration after the first dose

    Time frame: From 0 to 168 hours after trial product administration (Day 1)

    Measured in hours

  10. Cmax,I287,SS (for insulin 287) - Maximum observed serum insulin 287 concentration after the last dose

    Time frame: From 0 to 168 hours after trial product administration (Day 50)

    Measured in pmol/L

  11. tmax,I287,SS (for insulin 287) - Time to maximum observed serum insulin 287 concentration after the last dose

    Time frame: From 0 to 168 hours after trial product administration (Day 50)

    Measured in hours

  12. t½,I287,SS (for insulin 287) - Terminal half-life for insulin 287 at steady state

    Time frame: Terminal part of the serum insulin 287 concentration-time curve where the curve is well approximated by a straight line on logarithmic scale after last trial product administration (Day 50)

    Measured in hours

  13. CI287,trough (for insulin 287) - Serum insulin 287 trough concentration

    Time frame: Measured at the end of each dosing interval 168 hours after trial product administration (Day 8, 15, 22, 29, 36, 43, 50 and 57)

    Measured in pmol/L

  14. AUCIGlar,τ,SS (for insulin glargine) - Area under the serum insulin glargine concentration-time curve during one dosing interval at steady state

    Time frame: From 0 to 24 hours after trial product administration (Day 14)

    Measured in pmol*h/L

  15. Cmax,IGlar,SS (for insulin glargine) - Maximum observed serum insulin glargine concentration at steady state

    Time frame: From 0 to 24 hours after trial product administration (Day 14)

    Measured in pmol/L

  16. tmax,IGlar,SS (for insulin glargine) - Time to maximum observed serum insulin glargine concentration at steady state

    Time frame: From 0 to 24 hours after trial product administration (Day 14)

    Measured in hours

  17. CIGlar,trough (for insulin glargine) - Serum insulin glargine trough concentration

    Time frame: Measured at the end of each dosing interval 24 hours after trial product administration (Day 4, 7, 14 and 15)

    Measured in pmol/L

  18. Number of adverse events (AEs)

    Time frame: From first trial product administration (Day 1) to end of last dosing interval (Day 57 for insulin 287, day 15 for IGlar)

    Number of events

  19. Number of hypoglycaemic episodes

    Time frame: From first trial product administration (Day 1) to end of last dosing interval (Day 57 for insulin 287, day 15 for IGlar)

    Number of episodes

  20. Change in anti-insulin 287 antibody level

    Time frame: From first insulin 287 administration (Day 1) to Follow-up visit (visit 25, day 106)

    Measured in % B/T (percentage of bound tracer measured after precipitation to total tracer)

  21. Change in anti-insulin 287 antibody titres

    Time frame: From first insulin 287 administration (Day 1) to Follow-up visit (visit 25, day 106)

    Number of dilutions

  22. Positive cross-reactive anti-human insulin antibodies

    Time frame: At the follow-up visit (Visit 25, day 106)

    Number of patients with/without positive cross-reactive anti-human insulin antibodies

Sponsors and collaborators

Lead sponsor

Novo Nordisk A/S

Industry

Registry information

Official study title

A Trial Investigating the Pharmacokinetics and Pharmacodynamics of NNC0148-0287 C (Insulin 287) at Steady State Conditions in Subjects With Type 1 Diabetes

Important dates

Study start
2018
Primary completion
2020
Study completion
2020
First posted
Oct 30, 2018
Registry last updated
Mar 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.